Search
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Bevirimat
go.drugbank.com/drugs/DB06581InvestigationalIt is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos. … Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid.
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnIt was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[A249885] Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.
Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...
Lutropin alfa
go.drugbank.com/drugs/DB00044ApprovedInvestigationalIt is a heterodimeric glycoprotein made up of monomeric units.
Hepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnIn Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. … Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen.
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalThe antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation … [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology.
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]